Showing 2021-2030 of 2526 results for "".
- Oertli Launches New Silicone Application Adapterhttps://modernod.com/news/oertli-launches-new-silicone-application-adapter/2479114/Oertli announced it has released a new silicone application that is designed to allow for more user-friendly and efficient surgical preparation. The Oertli silicone application sets deliver fast injection and extraction of silicone oil, according to a company news release. The universal vi
- US Patents for Nicox’s Vyzulta (Latanoprostene Bunod) Eligible for Patent Term Extensionhttps://modernod.com/news/us-patents-for-nicoxs-vyzulta-latanoprostene-bunod-eligible-for-patent-term-extension/2479103/Nicox SA announced that the United States Patent and Trademark Office (USPTO) has determined that three U.S. composition of matter patents covering latanoprostene bunod, commercialized as Vyzulta (latanoprostene bunod ophthalmic solution), 0.024%, are eligible for patent term extension, potential
- Study Identifies Mechanism that May Cause Blindnesshttps://modernod.com/news/study-identifies-mechanism-that-may-cause-blindness/2479090/Using laboratory-grown roundworms as well as human and mouse eye tissue, University of Maryland School of Medicine (UMSOM) researchers have identified a new potential mechanism for age-related macular degeneration—the leading cause of blindness among older adults. The UMSOM researchers say
- Ocumension Therapeutics Licenses Alimera’s Fluocinolone Acetonide Intravitreal Implant in Chinahttps://modernod.com/news/ocumension-therapeutics-licenses-alimeras-fluocinolone-acetonide-intravitreal-implant-in-china/2479075/Alimera Sciences announced that Ocumension Therapeutics has acquired an exclusive license agreement for Alimera’s 0.19mg fluocinolone acetonide intravitreal implant, which Alimera markets elsewhere under the trademark Iluvien. The license grants Ocumension the rights to develop and commercialize
- World Council of Optometry Passes Resolution Calling for a Standard of Care for Myopia Managementhttps://modernod.com/news/world-council-of-optometry-passes-resolution-calling-for-a-standard-of-care-for-myopia-management/2479073/The World Council of Optometry (WCO) Board of Directors unanimously approved a resolution advising optometrists to incorporate a standard of care for myopia management within their practices. “Myopia is increasing at an alarming rate, as are the risks for vision impairment associated with
- Santen Announces Global Research Initiative to Study and Develop New Treatments for Glaucomahttps://modernod.com/news/santen-announces-global-research-initiative-to-study-and-develop-new-treatments-for-glaucoma/2479067/Santen announced a research initiative with scientists from Massachusetts Eye and Ear, and Ulster University, UK, to research and develop novel treatments for glaucoma. The aim
- Essilor to Present New Results for its Stellest Lens for Children With Myopiahttps://modernod.com/news/essilor-to-present-new-results-for-its-stellest-lens-for-children-with-myopia/2479062/Essilor will unveil pivotal 2-year clinical trial results of its Stellest lens for myopia. The 2-year results demonstrate that Essilor Stellest lenses slow down myopia progression by 67% on average, when compared to single vision lenses, when worn at least 12 hours a day,1 according to
- LumiThera Announces Topline Data in the European Multicenter LIGHTSITE II Study to Treat Dry AMDhttps://modernod.com/news/lumithera-announces-topline-data-in-the-european-multicenter-lightsite-ii-study-to-treat-dry-amd/2479059/LumiThera announced positive findings in its LIGHTSITE II multicenter clinical trial in dry age-related macular degeneration (AMD) patients. The prospective, double-masked, randomized, multicenter, European Union post-marketing clinical trial, titled LIGHTSITE II, was conducted in eight re
- FDA Approves Bausch + Lomb ClearVisc Dispersive Ophthalmic Viscosurgical Device (OVD)https://modernod.com/news/fda-approves-bausch-lomb-clearvisc-dispersive-ophthalmic-viscosurgical-device-ovd/2479058/Bausch + Lomb, announced that the FDA has approved ClearVisc dispersive ophthalmic viscosurgical device (OVD) for use in ophthalmic surgery. “OVDs play a critical role in ophthalmic surgery, and ClearVisc offers surgeons unique advantages that are designed to contribute to surgical safety
- OneSight Partners With Anthem Blue Cross and Blue Shield Foundation to Provide Free Eye Exams and Glasses in Cincinnatihttps://modernod.com/news/onesight-partners-with-anthem-blue-cross-and-blue-shield-foundation-to-provide-free-eye-exams-and-glasses-in-cincinnati/2479049/Preventative care visits have dropped significantly over the course of the pandemic, and this is especially true in under-served communities. That’s why the Anthem Blue Cross and Blue Shield Foundation teamed up with OneSight, a leading global vision care nonprofit, to provide free eye exams and